JHP Pharmaceuticals Adds Second Product to Multi-Year Contract Manufacturing Agreement
News Mar 02, 2012
JHP Pharmaceuticals has added a second product to an established multi-year contract with an undisclosed pharmaceutical company. JHP will be responsible for manufacturing and supply of an injectable anesthetic agent.
Stuart Hinchen president and CEO of JHP stated, “We are very pleased that JHP was chosen again by this well- established customer, as it speaks to their satisfaction with our work. We recently successfully completed an FDA (CBER) Pre-Approval Inspection in support of a biologic product launch for another long-term contract customer. JHP’s approach in meeting contract customer needs in a timely fashion creates an environment where customers are confident bringing additional manufacturing needs to us. Customers also rely on our extensive experience working with products throughout their life cycle which results in continuity of supply and program efficiencies.”
Hinchen noted, “JHP’s cGMP compliance record and established infrastructure combined with a broad and deep experience base have established a foundation that supports growth with both new and long-term customers.”
JHP’s Rochester, Michigan manufacturing site has a solid history of manufacturing a broad range of sterile product types including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE